Promising new targeted agents in head and neck cancer.
Siu
Lillian L
LL
Department of Medical Oncology, University of Toronto, Toronto, ON, Canada. lillian.siu@uhn.on.ca
D064127:Aurora Kinases; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000201:enzymology; D000069439:Dasatinib; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D051416:Focal Adhesion Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000627:therapeutic use; D020123:Sirolimus / Q000627:therapeutic use; D013844:Thiazoles / Q000627:therapeutic use; D019061:src-Family Kinases / Q000037:antagonists & inhibitors
D004791:Enzyme Inhibitors; D011743:Pyrimidines; D013844:Thiazoles; D051416:Focal Adhesion Protein-Tyrosine Kinases; D019061:src-Family Kinases; D064127:Aurora Kinases; D017346:Protein Serine-Threonine Kinases; D000069439:Dasatinib; D020123:Sirolimus